| Literature DB >> 20625243 |
Dong Woo Kang1, Gyesik Min, Do Yoon Park, Ki Whan Hong, Do Sik Min.
Abstract
Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood. Phospholipase D (PLD) is overexpressed in various types of cancer tissues and has been implicated as a critical factor in inflammation and carcinogenesis. However, whether rebamipide is involved in the regulation of PLD in gastric cancer cells is not known. In this study, we showed that rebamipide significantly suppressed the expression of both PLD1 and PLD2 at a transcriptional level in AGS and MKN-1 gastric cancer cells. Downregulation of PLD expression by rebamipide inhibited its enzymatic activity. In addition, rebamipide inhibited the transactivation of nuclear factor kappa B (NFkappaB), which increased PLD1 expression. Rebamipide or PLD knockdown significantly suppressed the expression of genes involved in inflammation and proliferation and inhibited the proliferation of gastric cancer cells. In conclusion, rebamipide-induced downregulation of PLD may contribute to the inhibition of inflammation and proliferation in gastric cancer.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20625243 PMCID： PMC2928928 DOI： 10.3858/emm.2010.42.8.056
Source DB: PubMed Journal: Exp Mol Med ISSN： 1226-3613 Impact factor: 8.718